275 related articles for article (PubMed ID: 34414843)
21. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S; Dubois J; Nasserinejad K; Dobber JA; Mellink C; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken H; Levenga H; Tick LW; Terpstra WE; Tonino SH; Boyer M; Mobasher M; Levin MD; Kater AP;
Lancet Haematol; 2022 Mar; 9(3):e190-e199. PubMed ID: 35240075
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
25. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Lovell AR; Sawyers J; Bose P
Expert Opin Pharmacother; 2023; 24(11):1307-1316. PubMed ID: 37226798
[TBL] [Abstract][Full Text] [Related]
26. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
27. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
[TBL] [Abstract][Full Text] [Related]
28. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Roeker LE; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
30. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
Yin Y; Athanasiadis P; Karlsen L; Urban A; Xu H; Murali I; Fernandes SM; Arribas AJ; Hilli AK; Taskén K; Bertoni F; Mato AR; Normant E; Brown JR; Tjønnfjord GE; Aittokallio T; Skånland SS
Clin Cancer Res; 2022 Oct; 28(20):4444-4455. PubMed ID: 35998013
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
32. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
34. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
[TBL] [Abstract][Full Text] [Related]
36. Current strategies to create tailored and risk-adapted therapies for CLL patients.
Cramer P; Eichhorst B; Reinhardt HC; Hallek M
Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
[TBL] [Abstract][Full Text] [Related]
37. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
